Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine and EX/RP in OCD
NCT02062658Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Dec 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in obsessive compulsive disorder (OCD), sponsored by New York State Psychiatric Institute. Primary endpoint: Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale at 2 weeks. Started Dec 2013; status: completed.
02
Drugs
ketamine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT02062658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062658.